Prime Medicine (PRME) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Prime Medicine (PRME) has outperformed ProKidney (PROK) over the past year, losing 33.6% versus a loss of 47.0%. Prime Medicine is the larger company by market cap ($707.4 million vs $626.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRME | PROK |
|---|---|---|
| Share price | $3.90 | $1.57 |
| Market cap | $707.37M | $626.72M |
| 1-day change | +11.43% | -1.87% |
| YTD return | +12.39% | -29.91% |
| 1-year return | -33.56% | -46.96% |
| EPS (TTM) | $-1.07 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.85 | $3.48 |
| 52-week low | $2.67 | $1.30 |
| Distance from 52-week high | -43.07% | -54.89% |
| Average volume | 3.32M | 1.31M |
| Shares outstanding | 181.38M | 208.93M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRME has outperformed PROK by 13.4 percentage points over the past year.
PRME vs PROK FAQ
Which is bigger, Prime Medicine or ProKidney?
Prime Medicine (PRME) is larger, with a market capitalization of $707.37M compared with $626.72M for ProKidney (PROK).
Which stock has performed better over the past year, PRME or PROK?
PRME returned -33.56% over the past 12 months, compared with -46.96% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are Prime Medicine and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.